| Dr Simone A Fearon, MD | |
|
1532 Lone Oak Rd Ste 415, Paducah, KY 42003-7943 | |
| (270) 442-0103 | |
| Not Available |
| Full Name | Dr Simone A Fearon |
|---|---|
| Gender | Female |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 25 Years |
| Location | 1532 Lone Oak Rd Ste 415, Paducah, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255522801 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lourdes Hospital | Paducah, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercy Health Physicians Kentucky Specialty Care Llc | 1456777069 | 97 |
News Archive
Results from the LESSON I trial presented today provide preliminary evidence for the therapeutic benefit of the newer generation everolimus-eluting stent over the previous gold standard, the early generation sirolimus-eluting stent. Moreover, LESSON I provides evidence that the formation of blood clots (stent thrombosis) - the principal shortcoming of early generation drug-eluting stents - may be diminished with the newer generation everolimus-eluting stent.
Can wearable technology make us well? Does the simple act of strapping a monitor to our arm modify our behaviour? Could these tiny devices provide doctors with vital information to reduce our risk of becoming unwell?
Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed two patent infringement lawsuits against Cellectis SA and a number of its affiliates in the U.S. District Court for the Eastern District of North Carolina.
We've known about chemicals that can be light-activated for about five to ten years now. They've mainly all been applied to neurons and, more specifically, the retina. Nobody has ever really looked at any tissues outside of the nervous system.
› Verified 3 days ago
| Entity Name | Pinelake Physician Practice Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295960532 PECOS PAC ID: 6800797507 Enrollment ID: O20040115001094 |
News Archive
Results from the LESSON I trial presented today provide preliminary evidence for the therapeutic benefit of the newer generation everolimus-eluting stent over the previous gold standard, the early generation sirolimus-eluting stent. Moreover, LESSON I provides evidence that the formation of blood clots (stent thrombosis) - the principal shortcoming of early generation drug-eluting stents - may be diminished with the newer generation everolimus-eluting stent.
Can wearable technology make us well? Does the simple act of strapping a monitor to our arm modify our behaviour? Could these tiny devices provide doctors with vital information to reduce our risk of becoming unwell?
Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed two patent infringement lawsuits against Cellectis SA and a number of its affiliates in the U.S. District Court for the Eastern District of North Carolina.
We've known about chemicals that can be light-activated for about five to ten years now. They've mainly all been applied to neurons and, more specifically, the retina. Nobody has ever really looked at any tissues outside of the nervous system.
› Verified 3 days ago
| Entity Name | Mercy Health Physicians Kentucky Specialty Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700408093 PECOS PAC ID: 1456777069 Enrollment ID: O20200813001096 |
News Archive
Results from the LESSON I trial presented today provide preliminary evidence for the therapeutic benefit of the newer generation everolimus-eluting stent over the previous gold standard, the early generation sirolimus-eluting stent. Moreover, LESSON I provides evidence that the formation of blood clots (stent thrombosis) - the principal shortcoming of early generation drug-eluting stents - may be diminished with the newer generation everolimus-eluting stent.
Can wearable technology make us well? Does the simple act of strapping a monitor to our arm modify our behaviour? Could these tiny devices provide doctors with vital information to reduce our risk of becoming unwell?
Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed two patent infringement lawsuits against Cellectis SA and a number of its affiliates in the U.S. District Court for the Eastern District of North Carolina.
We've known about chemicals that can be light-activated for about five to ten years now. They've mainly all been applied to neurons and, more specifically, the retina. Nobody has ever really looked at any tissues outside of the nervous system.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Simone A Fearon, MD 2200 Jefferson Ave Fl 5, Toledo, OH 43604-7102 Ph: () - | Dr Simone A Fearon, MD 1532 Lone Oak Rd Ste 415, Paducah, KY 42003-7943 Ph: (270) 442-0103 |
News Archive
Results from the LESSON I trial presented today provide preliminary evidence for the therapeutic benefit of the newer generation everolimus-eluting stent over the previous gold standard, the early generation sirolimus-eluting stent. Moreover, LESSON I provides evidence that the formation of blood clots (stent thrombosis) - the principal shortcoming of early generation drug-eluting stents - may be diminished with the newer generation everolimus-eluting stent.
Can wearable technology make us well? Does the simple act of strapping a monitor to our arm modify our behaviour? Could these tiny devices provide doctors with vital information to reduce our risk of becoming unwell?
Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed two patent infringement lawsuits against Cellectis SA and a number of its affiliates in the U.S. District Court for the Eastern District of North Carolina.
We've known about chemicals that can be light-activated for about five to ten years now. They've mainly all been applied to neurons and, more specifically, the retina. Nobody has ever really looked at any tissues outside of the nervous system.
› Verified 3 days ago
Mr. Danny Neale Butler, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2603 Kentucky Avenue, Suite 303, Paducah, KY 42003 Phone: 270-443-2900 Fax: 270-443-7122 | |
Winston Chua, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2603 Kentucky Ave, Suite 403, Paducah, KY 42003 Phone: 270-444-3930 Fax: 270-442-5284 | |
Lingaiah Chandrashekar, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 225 Medical Center Dr Ste 308, Paducah, KY 42003 Phone: 270-443-0777 Fax: 270-443-0999 | |
Gary Bodnarchuk, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1532 Lone Oak Rd, Suite 310, Paducah, KY 42003 Phone: 270-443-0777 Fax: 270-443-0999 | |
Dr. Bradley B Mcelroy, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2601 Kentucky Ave, Suite 301, Paducah, KY 42003 Phone: 270-575-3113 Fax: 270-575-3135 | |
Benjamin Howard Thompson, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2501 Kentucky Ave, Paducah, KY 42003 Phone: 270-575-8472 | |
Joseph A Bassi Ii, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 3131 Parisa Dr, Paducah, KY 42003 Phone: 270-444-8000 Fax: 270-444-8302 |